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Abstract Acute rhinosinusitis (ARS) is defined as an
inflammation of the mucosa of the nose and paranasal
sinuses and affects 1–5 % of general population in Europe.
Sinonasal diseases represent the main cause of smell
alterations in adult patients and lead to mucosal congestion,
increased quantity and density of secretions and altered
mucociliary transport. For this reason the odorous mole-
cules contained in the inspired air, cannot interact with the
olfactory epithelium. Medical therapy of ARS has to
reduce the severity and duration of symptoms and prevent
complications. Recent studies have shown that Sodium
hyaluronate modulate inflammation and has a reparative
effect on the nasal mucosa. 48 patients affected by acute
rhinosinusitis proven by CT scan, were enrolled. They were
submitted to nasal endoscopy, olfactometric and mucocil-
iary transport evaluation (MCTt), Visual Analogue Scale
Questionnaire (VAS) at T0, after 14–18 days (T1) and after
30–35 days (T2). The patients were randomized into two
treatment groups, A and B, and were treated for 30 days;
each group was composed of 24 subjects. All patients
received Levofloxacin (500 mg for 10 days) and Pred-
nisone (50 mg for 8 days, 25 mg for 4 days and 12, 5 mg
for 4 days). Moreover, Group A received twice a day for
30 days high molecular weight Sodium Hyaluronate (3 %)
plus saline solution (3 mL sodium chloride-NaCl—0.9 %)
using a nebulizer ampoule for nasal douche. Group B
received twice a day for 30 days saline solution (6 mL
sodium chloride-NaCl—0.9 %) using a nebulizer ampoule
for nasal douche. At T1 Group A shown lower values in
MCTt and threshold score was significantly higher than in
Group B. VAS showed statistically significant differences
between the two groups, in particular for smell, nasal
obstruction and for nasal discharge. At T2 Group A MCTt
was significantly lower than in Group B; odour threshold
improved in both groups but in Group A was still signifi-
cantly higher than in Group B. No statistical differences
between two groups regarding odour discrimination and
odour identification were confirmed at T1 and T2. VASy
score showed statistically significant differences between
the two groups only for nasal discharge.
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Introduction
Acute rhinosinusitis (ARS) is defined as an inflammation of
the mucosa of the nose and paranasal sinuses characterized
by two or more of these symptoms: nasal congestion, nasal
discharge or post-nasal drip, facial pain or pressure, loss or
reduction of smell. Additional symptoms such as headache
or fever may occur [1].
ARS affects 1–5 % of general population in Europe; it
has a substantial socio-economic impact and the recurring
form may have a negative impact on quality of life [2].
Sinonasal diseases represent the main cause of smell
alterations in adult patients [3]. Inflammation of the sino-
nasal mucosa leads to mucosal congestion, increased
quantity and density of secretions and altered mucociliary
transport. In this condition, the odorous molecules con-
tained in the inspired air, cannot interact with the olfactory
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epithelium due to alterations of the conductive mechanism
but also to local inflammation, which impedes the arrival of
odorants to the receptors of the cilia [4]. The primary goal
of medical therapy of ARS is to reduce the severity and
duration of symptoms and prevent complications.
In the last few years, intranasal sodium hyaluronate is
being used more often in the treatment of chronic sinonasal
diseases [5–7]. Sodium hyaluronate has a reparative effect
on the nasal mucosa; it modulates mucosal inflammation
and increases mucociliary clearance even after nasal and
sinus surgery. This results in an overall restoration of the
tissue elasticity and of the epithelial physiological func-
tions [8, 9].
This is the first comparative study performed to assess
eventual deficits of smell conduction in 2 group of patients
suffering from acute bacterial rhinosinusitis, receiving
treatment with systemic antibiotics and steroids as well as
coadjuvant treatment with high molecular weight intranasal
sodium hyaluronate in one group and saline solution in the
other.
Material and method
In this study, we enrolled 48 consecutive patients who
came to our attention at the Rhino-Allergology clinic,
Department of Sense Organs of Sapienza University, from
December 2014 to April 2015.
All patients were thoroughly informed about the study
and they signed an informed consent.
All patients presented one episode of acute bacterial
rhinosinusitis symptoms according to the EPOS guidelines
(T0) and they underwent according to the design of the
study:
• Anamnesis;
• ENT examination with nasal endoscopy using by a
2.7 mm 0 rigid endoscope;
• Visual Analog Scale (VAS) Questionnaire for subjec-
tive assessment of symptoms: nasal obstruction, nasal
discharge, post-nasal drip, facial pain (0 = absent;
1 = mild; 2 = moderate; 3 = severe) and olfactory
perception (0 = normal; 1 = decreased; 2 = absent);
• Olfactometric examination by Sniffin’ Sticks method
(Bughart, Wedel, Germany). During the test the patient
was asked to smell penn-like devices that are filled with
odorant and divided into three series; The first series
comprises 16 ascending concentration of n-butanolo
and permits the assessment of the threshold (T); the
second series features two identical substances and one
different substance to asses discrimination (D) and the
third series consist of 16 odours of common substances
to asses identification (I). A score between 0 and 16 is
given for each of the three subtests. The sum of the
three scores give a definitive TDI score between 0 and
48, which determines whether the patients has anosmia
(TDI B 15), hyposmia (TDI[ 15 = 30) or normosmia
(TDI[ 30) [10].
• Nasal MCTt determination using some charcoal pow-
der placed on the head of the inferior turbinate and
evaluating the moment in which a blackish colouring
appears in the oro-pharynx (normal
values = 12 ± 3 min);
• CT scan of nasal and sinusal structures with axial,
coronal and sagittal projections to exclude nasal
polyposis conditions.
ENT examination with nasal endoscopy, VAS ques-
tionnaire and olfactometric evaluations were performed
after 14–18 days (T1) and after 30–35 days (T2).
The patients were randomized into two treatment
groups, A and B, and were treated for 30 days; each group
was composed of 24 subjects. All patients received
antibiotic and steroid systemic therapy consisting of
Levofloxacin (500 mg for 10 days) and Prednisone (50 mg
for 8 days, 25 mg for 4 days and 12, 5 mg for 4 days).
Moreover, Group A received twice a day for 30 days high
molecular weight (800,000–1,000,000 Daltons) Sodium
Hyaluronate (3 %) plus saline solution (3 mL sodium
chloride-NaCl- 0.9 %) using a nebulizer ampoule for nasal
douche (Rinowash, Air Liquide Medical System Spa).
Group B received twice a day for 30 days saline solution
(6 mL sodium chloride-NaCl—0.9 %) using a nebulizer
ampoule for nasal douche (Rinowash, Air Liquide Medical
System Spa).
Statistical analysis was performed by comparing the
data of the two groups of treatment at T0, T1 and T2. Chi-
square test was used for categorical variables and non-
parametric Wilcoxon Mann–Whitney test was used for
continuous variable. Continuous variables were presented
as median and interquartile range (IQR). All data were
analysed using Stata SE 10.1 System.
Results
We enrolled 48 patients divided into two groups. Group A
was composed of 24 patients, 12 male and 12 female, mean
age of 44 years (38–50 IQR); Group B was composed of 24
patients, 14 male and 10 female, mean age of 43 years
(35–55 IQR). All patients enrolled in the study completed
all evaluations and no episodes of drug intolerance
occurred.
CT results shown rhinosinusitis with congestion on
osteo-meatal complex in 100 % of patients. Rhinosinusitis
involved ethmoidal sinus, both ethmoidal and maxillar
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sinuses, both ethmoidal and frontal sinuses, in 15, 65 and
20 % of cases, respectively, in Group A and in 25, 45 and
30 %, respectively, in Group B.
Table 1 shows the baseline characteristics of the patients
making up the two groups: there were no statistical dif-
ferences between the two groups in demographic, olfac-
tometric data (threshold, discrimination, and identification)
and MCT time.
The self-assessment questionnaires (VAS) score showed
statistically significant differences between the two groups
regarding nasal discharge (p = 0.010) and post-nasal drip
(p = 0.02) (Table 1).
Table 2 shows T1 results after 14-18 days’ treatment. In
Group A MCTt was significantly lower than in Group B:
the median value was 15 min (IQR: 12.5–15) in Group A
and 20 min (IQR: 15–20) in Group B (p = 0.003).
In Group A odour threshold was significantly higher
than in Group B: median threshold score was 8 (IQR:
5–8.5) in Group A and 5.5 (IQR: 4–7) in Group B
(p = 0.042). There were no statistical differences between
the two groups regarding odour discrimination and odour
identification.
The replies to the self-assessment questionnaires (VAS)
showed statistically significant differences between the two
groups, in particular for smell (p = 0.018), nasal obstruc-
tion (p\ 0.001) and for nasal discharge (p = 0.006)
(Table 2).
Table 3 shows T2 results after 30 days treatment. In
Group A MCTt was significantly lower than in Group B:
the median value was 15 min in both groups but there was
a different distribution of values (IQR: 10–15 in Group A,
IQR: 15–15 in Group B) (p = 0.021). Odour threshold
improved in both groups but in Group A was still signifi-
cantly higher than in Group B: median threshold score was
10 (IQR: 8–11) in Group A and 8 (IQR: 7.5–9) in Group B
(p = 0.007). No statistical differences between two groups
regarding odour discrimination and odour identification
were confirmed.
The self-assessment questionnaires (VAS) score showed
statistically significant differences between the two groups
only for nasal discharge (p = 0.040, same median, differ-
ent distribution) (Table 3).
Discussion
Via the olfactory neuroepithelium and the central nervous
system processes, humans are able to recognize and dis-
criminate many different odorant molecules. The interac-
tion of odorants to a specific binding receptor protein in the
cilia of olfactory neuroepithelium represents the first step
in the identification and detection of chemically distinct
odorants.
There are many causes of olfactory dysfunction; in
many cases it is determined by inflammation of the upper
respiratory tract and the rhinosinus diseases [11, 12].
Several studies have reported different aetiological factors
in patients with smell disorders. As reported by Keller and
Malasapina, sinonasal etiology has been reported in a
percentage ranging from 14 to 48 %, according to different
case studies [13]. In our previous study conducted in 2006,
rhinosinusal pathologies were the aetiopathological factor
indentified in 6.3 % of 243 patients reporting olfactory
dysfunction [14].
In acute rhinosinusitis, the irritative-inflammatory state
may determine reduction or loss of smell by means dual
mechanism of action. First, mucosal edema and congestion,
and the alteration of quantity and density of the nasal
secretions, cause a mechanical conduction block of odor-
ous substances that can no longer interact with the binding
Table 1 Demographic data and
baseline characteristics of
patients (T0)
Group A (N = 24) Group B (N = 24) p
Male, n (%) 12 (50.0 %) 14 (58.3 %) 0.562
Age(years), median (IQR) 44 (38–50) 43 (35–55) 0.975
MCTt, median (IQR) 20 (20–25) 20 (20–25) 0.853
Smell
Threshold, median (IQR) 3 (1–5) 3 (1.5–5.5) 0.675
Discrimination, median (IQR) 6 (5–8) 7 (5–8) 0.332
Identification, median (IQR) 8 (6.5–9.5) 8 (7–9) 0.908
TDI, median (IQR) 16.5 (14–21.5) 19 (15.5–22) 0.352
VAS
Smell 0–2 2 (1–2) 1.5 (1–2) 0.388
Obstruction 0–3 2 (1.5–2) 1.5 (1–2) 0.142
Discharge 0–3 2 (2–3) 1 (1–2) 0.010
Post-nasal drip 0–3 1 (0–2) 0 (0–1) 0.022
Facial pain 1 (1–2) 1 (1–2) 0.274
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receptor. Furthermore, the local edema and the products of
inflammation may damage the primary olfactory neuron
and could inhibit the transmission of synaptic impulses [4].
In some studies, it was observed that the severity of
olfactory loss depends on degree and duration of these
inflammatory changes [15]. Even if many pathophysio-
logical mechanisms of smell dysfunction were thoroughly
investigated, clinical and therapeutic options are still
limited.
Considering the real incidence of acute rhinosinusitis,
we can understand the real impact that the alteration of
smell can have on quality of life.
Sodium hyaluronate, a high molecular weight non-sul-
phated glycosaminoglycan, is the major component in most
organs and tissue and it has many functions. It is the
principal component of the extracellular matrices of the
respiratory epithelial cells and gland serous cells in the
mucosa of upper airways and tracheobronchial tracts.
Sodium hyaluronate promotes tissue proliferation and tis-
sue remodelling and modulates cell migration and
chemotaxis, angiogenesis and inflammatory responses
[16, 17]. Inflammatory factors, as free radicals and
enzymes, lead to a fragmentation of hyaluronic acid and
the low molecular weight molecules which are formed, act
as proinflammatory mediators, promoting and supporting
the immune response. For this reason, the presence of high
molecular weight of hyaluronic acid suppresses immune
system function and limits the inflammatory response
[9, 18]. Furthermore, on the nasal mucosa sodium hyalur-
onate can increase mucociliary activity and regulates
vasomotor tone and serous and mucous gland secretion
[19, 20].
In the last few years, some authors have conducted
clinical studies to evaluate the effect of sodium hyaluronate
on the nasal mucosa. Forteza et al. demonstrated that
sodium hyaluronate stimulates ciliary clearance of foreign
material HA and regulates the activity of the enzymes,
which are essential for maintaining the homeostasis at the
apical surface [21]. Numerous studies have evaluated the
role of sodium hyaluronate in the prevention of
Table 2 Comparing data at T1
Group A (N = 24) Group B (N = 24) p
MCTt, median (IQR) 15 (12.5–15) 20 (15–20) 0.003
Smell
Threshold, median (IQR) 8 (5–8.5) 5.5 (4–7) 0.042
Discrimination, median (IQR) 10 (8–11) 9 (8–10) 0.426
Identification, median (IQR) 11 (10–12) 11 (9.5–12) 0.585
TDI, median (IQR) 28.5 (24.5–30) 25 (22–28.5) 0.111
VAS
Smell 0–2 0 (0–1) 1 (1–1) 0.018
Obstruction 0–3 0 (0–0.5) 1 (1–1) <0.001
Discharge 0–3 0.5 (0–1) 1 (1–2) 0.006
Post-nasal drip 0–3 0 (0–0) 0 (0–0) 0.714
Facial pain 0 (0–1) 0 (0–1) 0.700
Table 3 Comparing data at T2
Group A (N = 24) Group B (N = 24) p
MCTt, median (IQR) 15 (10–15) 15 (15–15) 0.021
Smell
Threshold, median (IQR) 10 (8–11) 8 (7.5–9) 0.007
Discrimination, median (IQR) 12 (10–13) 11 (10–12) 0.400
Identification, median (IQR) 13 (11.5–14) 13 (12–13) 0.271
TDI, median (IQR) 35 (30.5–37) 32 (29–33.5) 0.064
VAS
Smell 0-2 0 (0–0) 0 (0–0) 1.000
Obstruction 0–3 0 (0–0) 0 (0–1) 0.335
Discharge 0–3 0 (0–0) 0 (0–1) 0.040
Post-nasal drip 0–3 0 (0–0) 0 (0–0.5) 0.125
Facial pain 0 (0–0) 0 (0–0) 0.388
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exacerbations of chronic rhinosinusitis and in the post-
operative tissue repair after sinonasal surgery, contributing
to the regeneration of the nasal mucosa and promoting
post-infection and post-operative remodelling actions
[6–8, 22–24].
In our study, we investigated the effects of sodium
hyaluronate in the treatment of acute rhinosinusitis. In
Group A we added, Sodium Hyaluronate (3 %) plus saline
solution (3 mL-NaCl—0.9 %) to antibiotic and steroid
therapy using a nebulizer ampoule for nasal douche and we
evaluated the patients enrolled after 14 (T1) and 30 (T2)
days’ therapy. All patients underwent MCT time evalua-
tion, an olfactometric examination by Sniffin’ Sticks
method for evaluation of odour threshold, odour discrimi-
nation and odour identification, and they filled out a VAS
questionnaire for subjective assessment of nasal obstruc-
tion, nasal discharge, post-nasal drip, facial pain and
olfactory perception.
During the first evaluation (T0), there were no statistical
differences among olfactory parameters. At the first clinical
control (T1), we have found that in Group A odour
threshold was significantly higher than in Group B. At the
second control (T2), odour threshold had improved both in
Group A and in the Group B, but the values were better in
Group A. There were no statistical differences between the
two groups regarding odour discrimination and odour
identification at T1 and T2 controls.
The evaluation of MCTt showed that after just 14 days
therapy (T1) the values were in accordance with the stan-
dard limits in Group A.
The data of subjective assessment of symptoms showed
that at T0 the nasal discharge and post-nasal drip scores
were worse in Group A than in Group B. Nevertheless, the
subjective data related to smell, nasal obstruction and nasal
discharge at the first control (T1) were better in Group A
than in Group B, and at the second control (T2) the only
statistical difference between the two groups regarded
nasal discharge.
Thus, our data show that sodium hyaluronate admin-
istered as adjuvant treatment, has improved odour
threshold, TMCt and subjective symptoms in Group A
after 14 days of therapy. The modulation of inflammation
and the reparative action in the nasal mucosa and in the
olfactory epithelium, as well as better mucociliary clear-
ance, have favoured a reduction of mucosal inflammation
and interaction between odorous molecules and olfactory
epithelium. After 30 days of therapy, there were no dif-
ferences between the two groups, except for the nasal
discharge symptom. Therefore, as shown by our data, the
effects of sodium hyaluronate in the treatment of acute
rhinosinusitis could facilitate fasten physiological recov-
ery of the nasal functions, reducing the severity and
duration of symptoms.
Conclusion
Olfaction is a critical physiological process of the nasal
airway that is related to a number of health and social
factors that are crucial for quality of life. Considering the
incidence of rhinosinusitis throughout the world and the
social costs associated with this condition, the search for a
drug that reduces the severity and duration of symptoms
becomes essential.
Therefore, several studies have demonstrated that
sodium hyaluronate might be a valuable option in the
management of chronic rhinosinusitis and in its post-op-
erative treatment. Our study shows that sodium hyaluronate
may also play an important role in the treatment of acute
rhinosinusitis favouring tissutal repair, restoring mucosal
function and reducing both the severity and duration of
symptoms.
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